With the potential development of new disease-modifying Alzheimer’s disease (AD) therapies,
simple, widely available screening tests are needed to identify which individuals, who are …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage are …

BACKGROUND: Numerous studies show that the cerebrospinal fluid biomarkers total tau (T-tau),
tau phosphorylated at threonine 181 (P-tau 181P ), and amyloid-β (1-42) (Aβ 1–42 ) …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …

Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising
results, there is increasing evidence suggesting that understanding alternative disease …

Importance Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread
implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate …

Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …